Skip to main content

Start your 7-day free trial today. Get Started →

Patent Examiner Pancham Bakshi

Art Unit 1623 · Organic & Medicinal Chemistry: Carbohydrates & Bio-Affecting Compositions · Tech Center 1600 · 336 applications since 2021

⚑ Hard: harder than 72% of examiners● Free examiner data

Pancham Bakshi is a USPTO patent examiner in Art Unit 1623 (Organic & Medicinal Chemistry: Carbohydrates & Bio-Affecting Compositions) who has examined 336 applications in filing years 2021–2025. Examiner Bakshi's allowance rate is 67.0%, below the 82.1% USPTO average; the examiner ranks harder than 72% of examiners. Applicants who held an examiner interview saw a 33.3 percentage-point lift in allowance in 2024.

Draft a response to Examiner BakshiSee the strategy data ↓

Data through March 2026 · Source: USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty: Hard
harder than 72% of examiners
Easier72nd percentileHarder
Allowance rate vs peers
Examiner Bakshi67.0%
Art Unit 162365.4%
USPTO average82.1%
Allowance rate
67.0%
▼ USPTO avg 82.1%
Applications
336
filing years 2021–2025
First-action allowance
9.9%
allowed on OA #1
Abandoned
20.8%
share of applications
Avg office actions
1.2
USPTO avg 1.2
Days to first OA
653
▲ USPTO 589
RCE rate
18.2%
USPTO 14.1%
Interview rate
26.2%
USPTO 21.5%

Examiner details

  • Art unit1623 · Organic & Medicinal Chemistry: Carbohydrates & Bio-Affecting Compositions
  • Title / gradePrimary Patent Examiner · GS-14
  • Service14 years
  • Phone(571) 270-3463
  • Email[email protected]
  • LocationAlexandria, VA 22314
  • On office actionsBakshi, Pancham
Full signatory authority

Examiner Bakshi can allow an application without a supervisory sign-off, which is why an examiner interview can be decisive.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions556 · Organic Compounds (Class 532-570 Series)536 · Organic Compounds: Carbohydrates (Class 532-570 Series)

How to improve your odds with Examiner Bakshi

  • The data favors an interview. Interviewed cases allowed 42.1 points higher in 2023, the largest measured lift on this docket.
  • Plan for the timeline. First office action averages 653 days vs the 589-day USPTO norm.
  • Expect a §112. Disclosure is the most-issued rejection (172), and applicants overcame it 80.4% of the time.
  • The data favored an RCE here. Cases with an RCE allowed at 100.0% versus 65.2% without in 2023.
  • Tighter claims have moved faster here. With a 67.0% allowance rate, appropriately scoped independent claims have tended to shorten prosecution.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility7 issued · 0.0% overcome
§102 Novelty149 issued · 71.3% overcome
§103 Obviousness162 issued · 76.8% overcome
§112 Disclosure172 issued · 80.4% overcome
Arguments that overcame §112 rejections🔒 Members

REMARKS: Applicant respectfully traverses the rejection under 35 U.S.C. §112. The specification provides written-description and enablement support for the claimed subject matter, and the claim terms are definite when read in light of the specification by one of ordinary skill in the art, at least because ...

Read every winning §112 argumentFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Bakshi?

Draft a response grounded in Examiner Bakshi's complete prosecution history: the rejection patterns, the interview record, and the arguments that have actually worked. Powered by Boundly AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Bakshi.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202318.2%100.0%65.2%+34.8pp
20229.4%100.0%66.7%+33.3pp
202123.8%72.7%62.4%+10.3pp

Recent outcomes

Free🔒 Case detail: members
App #TitleOutcomeOAsArguments & redline
17/489022Inhibitors of Aldose ReductasePatented1🔒 View
17/800131Tafoxiparin for the Treatment of PreeclampsiaPatented1🔒 View
18/660695Hepatitis B Antiviral AgentsPatented1🔒 View
17/912647Lipophilic Enantiomers of Desacetylglucosamine Muramyl Dipeptide with Anti-Inflammatory and Growth Promoting ActivityPatented1🔒 View
See all 336 dispositions with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Technology & expertise

Carbohydrate chemistryMedicinal chemistryBio-affecting compositionsOrganic synthesisTop CPC: C07H · A61K · C07D
About this examiner. Pancham Bakshi has examined 336 applications in Art Unit 1623 (Organic & Medicinal Chemistry: Carbohydrates & Bio-Affecting Compositions, Tech Center 1600). The docket skews toward carbohydrate chemistry, medicinal chemistry, bio-affecting compositions.

Frequently asked questions

What is Examiner Pancham Bakshi's allowance rate?
Examiner Bakshi's allowance rate is 67.0%, compared with the 82.1% USPTO average and 65.4% for Art Unit 1623, which places Examiner Bakshi harder than 72% of examiners.
Is Examiner Bakshi a hard examiner?
Somewhat — Examiner Bakshi ranks harder than 72% of examiners, in the 72nd difficulty percentile (hard), with a 67.0% allowance rate versus the 82.1% USPTO average and a higher RCE rate (18.2% versus 14.1%).
Do examiner interviews help with Examiner Bakshi?
The data says yes. Interviewed applications allowed 42.1 percentage points higher than non-interviewed ones in 2023 (100.0% versus 57.9%).
What is Examiner Bakshi's most common rejection?
§112 disclosure, issued 172 times in the data. Applicants overcame it 80.4% of the time, usually by amendment plus argument.
Is an RCE worth filing with Examiner Bakshi?
Often, yes — every measured year ran the same way. In 2023, applications with an RCE allowed at 100.0% versus 65.2% without one.
How long until the first office action from Examiner Bakshi?
About 653 days on average, versus the 589-day USPTO norm.
How do I contact Examiner Pancham Bakshi?
Examiner Bakshi can be reached by phone at (571) 270-3463 or by email at [email protected]. The examiner's direct line also appears on the first page of every office action.

Put Examiner Bakshi's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2025, updated monthly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Historical data is provided for informational purposes only; past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Pancham Bakshi, or see an error? Request a correction.